CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sirnaomics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sirnaomics Ltd
401 Professional Drive
Suite 280
Gaithersburg, MD  20879  United States Ticker: 22572257
Business Summary
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a multi-targeted siRNA therapeutic advancing clinical development across two oncology indications: squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Its STP707 is an intravenous siRNA therapeutic being evaluated in phase I clinical trial for multiple solid tumors, including colorectal, pancreatic, liver, and metastatic melanoma cancers. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes---Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer Hung FaiPoon 47 9/1/2025 10/15/2024
Company Secretary Yun TingYuen 33 11/30/2024 11/30/2024
Non-Executive Director YunlongOuyang 38 7/3/2025 7/3/2025
4 additional Officers and Directors records available in full report.

Business Names
Business Name
2257
SIRNAOMICS INC.

General Information
Number of Employees: 52 (As of 6/30/2025)
Outstanding Shares: 107,221,538 (As of 12/8/2025)
Stock Exchange: HKG
Email Address: info-office@sirnaomics.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, February 1, 2026